SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is trending after reporting quarterly results that exceeded expectations, driven by strength in its commercial segment and AI initiatives, sparking intense debate about the stock's valuation. The community is focused on the company's growth metrics, guidance, and the potential impact of AI on its future performance, while also arguing about whether the current price is justified. Some traders anticipate a continued rise, while others expect a pullback due to valuation concerns and broader market conditions.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

HIMS is trending as investors anticipate the upcoming earnings report, with the community split between bullish and bearish expectations. Discussions revolve around potential growth catalysts, such as new weight-loss and menopause treatments, and whether the company can maintain its growth trajectory. Some traders are wary of potential post-earnings volatility, while others are closely watching for a possible short squeeze amid high short interest.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to recent data from a confirmatory trial that failed to meet its primary endpoint, raising concerns despite an earnings beat; the community is actively debating the trial's impact and the company's future prospects. While some believe the selloff is an overreaction and a buying opportunity, others are worried about the long-term implications for Sarepta's PMO therapies and are looking to the upcoming conference call for clarity. Community members are also discussing potential for buyout.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending as investors await the FDA decision on the expanded indication for Revuforj in relapsed or refractory NPM1 mutated acute myeloid leukemia. The community is discussing the potential for a buyout, especially by Incyte, as well as comparing Revuforj's prospects against competitors. Some traders are anticipating a post-approval sell-off, while others are optimistic about the drug's commercial potential and long-term value.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to discussions around its potential role in the European AI infrastructure build-out, with some viewing it as a competitor to ASML.  The community is weighing the impact of recent news, including deals from competitors and Amazon's AI initiatives, on NBIS's future growth and market position.  Many are focused on the upcoming earnings report and potential new deals being announced.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a revised analyst rating to Buy with a higher target price, sparking community discussion about the company's potential. Community members are actively debating the future direction of the stock and comparing it to similar situations, as well as discussing possible takeover scenarios. Discussions also include sentiment around its earnings report and potential FDA-related news.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

NUVB is trending on positive sentiment around its first full quarter as a commercial-stage company, highlighted by 204 new patients receiving IBTROZI. The community is also focused on the durability profile of IBTROZI with a 50-month median duration of response, and progress in the pipeline with the first patient dosed for safusidenib. Discussions also center on the potential for a short squeeze, upcoming conference presentations, and comparisons to competitors in the oncology space.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending amidst mixed sentiment, with the stock facing significant downward pressure and community frustration often directed at the CEO. Discussions revolve around the high short interest and speculation on potential catalysts like the upcoming earnings report, the Northern Data acquisition, and the launch of the Rumble Wallet. Some investors express optimism tied to the company's relationship with Tether and political affiliations, while others highlight concerns over profitability and user growth.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors anticipate upcoming earnings and discuss the potential impact of autonomous vehicle technology, particularly following news of new partnerships. Community members are actively debating the stock's valuation and future growth prospects within the evolving mobility landscape. Bullish sentiment revolves around Uber's leadership position and expansion into new markets, while others express caution due to tariff concerns and general market volatility.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals (TERN) is trending due to positive Phase 1 data for its leukemia drug TERN-701, which analysts believe could disrupt the CML treatment landscape, driving an upgrade from William Blair. The community is actively discussing the potential for a capital raise following the surge, with some wary of a possible "scam street" manipulation while others see a strong buying opportunity. Recent Oppenheimer and Mizuho ratings contribute to the bullish sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems to Host Third Quarter 2025 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on...

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for...

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2...

Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of +250.00% and +9.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates

Ekso Bionics (EKSO) delivered earnings and revenue surprises of -3.33% and -55.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Delcath Systems Stock?

Investors need to pay close attention to DCTH stock based on the movements in the options market lately.

Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know 

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's  What You Should Know

Here's Why Momentum in Delcath Systems (DCTH) Should Keep going

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$9.52
Prev Close	$9.83
Open	$9.81
Dividend Yield	0.00%
50-Day Moving Average	$10.95
Beta	1.04
Avg. Volume	616,379.67
PE Ratio	216.04

52-Week High	$18.23
52-Week Low	$8.87
Market Capitalization	$343.87M
EPS (Annual)	-$0.9254
Price to Book	3.27
Revenue Per Employee	$387,552.08
Enterprise Value/EBITDA	N/A

DCTH
Delcath Systems Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DCTH News

DCTHDelcath Systems Inc